Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm receives $2.32m R&D tax incentive refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- PAR reports pain reduction in 145 people with osteoarthritis
- Paradigm Agreement With USA Past Players Network
- Paradigms Updated Corporate Presentation
- Paradigm Raises A$9 Million
- PAR reports pain reduction in oa patients
Later from Paradigm Biopharmaceuticals
- Paradigm in-licenses treatment for rare joint disease
- Paradigms AGM Presentation
- Paradigm reports consistent oa pain reduction
- PAR reports successful phase 2 clinical trial
- Presentation of phase 2 clinical trial results
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals